High out-of-pocket costs and rising list prices put therapies out of reach for many patients, strain employer-sponsored coverage, and drive public spending. Policy changes at the federal and state levels can reduce prices while preserving innovation—if they focus on competition, transparency, and smarter purchasing.
Why prices stay high
– Patent protections and strategic patenting delay generic and biosimilar competition.
– Complex supply chains with pharmacy benefit managers (PBMs), insurers, manufacturers, and distributors create opaque rebates and fees that don’t always reach patients at the point of sale.
– Limited negotiating power for some payers, especially in the commercial market, leaves list prices unconstrained.
– Regulatory barriers and market incentives slow adoption of lower-cost alternatives.
Policy levers with practical impact
1. Strengthen competition
– Facilitate faster market entry for generics and biosimilars by limiting patent abuse and streamlining FDA review pathways.
More entrants typically drive down prices.
– Encourage interchangeability standards and reduce barriers for biosimilar substitution at the pharmacy.
2. Increase purchasing power and negotiation
– Expand the ability of large public programs and coalitions of purchasers to negotiate prices directly with manufacturers. When payers can leverage volume, manufacturers often offer lower net prices.
– Promote multi-state purchasing pools for Medicaid and public employee plans to amplify negotiating leverage.
3. Reform PBM practices and rebate structures
– Require clearer disclosure of rebate flows and consider prohibitions on spread pricing where PBMs keep the difference between what they charge payers and reimburse pharmacies.
– Shift incentives away from list-price-driven rebates toward patient-centered cost-sharing that reflects net prices.
4. Enhance transparency
– Mandate transparent reporting of list prices, net prices after rebates, and R&D spending tied to pricing decisions. Transparency alone isn’t a cure, but it empowers regulators and payers to design targeted fixes.
5. Enable safe importation and reference pricing where appropriate
– Carefully structured importation programs and international reference pricing can provide immediate relief for high-cost products, particularly where domestic competition is lacking. Implementation should prioritize safety, supply security, and fair market incentives.
6. Promote value-based contracting
– Encourage outcomes-based agreements that align price with real-world effectiveness. Value-based contracts reduce costs for ineffective therapies and reward clinically superior products.
7. Address patent and exclusivity practices
– Tighten oversight of patent “evergreening” and abusive extensions while preserving incentives for genuine innovation. Faster challenges to weak patents can accelerate competition without undermining true advances.
Potential challenges and tradeoffs
– Negotiation and price controls can reduce revenue for manufacturers, which may influence R&D investment unless balanced with other incentives.
– Importation and reference pricing require robust supply chain oversight to avoid shortages and ensure product authenticity.
– Transparency and PBM reforms must be carefully designed to avoid unintended cost-shifting or administrative burdens.
Practical next steps for policymakers and stakeholders
– Combine short-term measures (transparency rules, PBM oversight, importation pilots) with longer-term reforms (patent policy, streamlined approval for generics/biosimilars).
– Build public-private coalitions that can pilot value-based purchasing models and multi-state purchasing arrangements.
– Center policy on patient affordability at the pharmacy counter—reduce out-of-pocket exposure and ensure rebates and discounts directly benefit consumers.
Meaningful progress on drug prices is achievable with a balanced policy mix that protects innovation while increasing competition, accountability, and fairness across the supply chain.